Among patients with severe calcific aortic valve stenosis who are at high risk for surgical intervention, transcatheter aortic valve replacement (TAVR) is a safe and effective treatment option1,2. The REPRISE I feasibility study3 was designed to assess the acute safety and performance of TAVR with the mechanically expandable, fully repositionable and retrievable LOTUS™ valve (Boston Scientific, Marlborough, MA, USA). In addition to controlled mechanical expansion, which facilitates precise positioning, the valve has a unique adaptive seal, resulting in minimal paravalvular aortic regurgitation. This report of five-year outcomes from the REPRISE I study represents the longest-term data available to date for the LOTUS valve.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com